Glaxosmithkline Share News (GSK)

Pharma CEOs in Davos put brave face on Trump presidency

By Ben Hirschler DAVOS, Switzerland, Jan 20 (Reuters) - Leaders of the global pharmaceutical industry, blasted by incoming U.S. President Donald Trump for "getting away with murder" on drug prices, are putting a brave face on the challenges in their biggest market. The following are c

GlaxoSmithKline nabs Astra's Luke Miels to head global pharma

(ShareCast News) - The president of GlaxoSmithKline's global pharmaceuticals division, Abbas Hussain, is leaving the company later this year, to be replaced by AstraZeneca's Luke Miels. Miels, who is currently executive vice president of Astra's European business, will report to current chief execut

UPDATE 2-GSK grabs Astra executive to replace pharma head

* Pharma head Hussain leaving GSK after missing top job * To be replaced by Luke Miels from AstraZeneca * Miels was head of Astra's European business (Adds interview with GSK CEO in Davos, further details) By Ben Hirschler and Paul Sandle LONDON/DAVOS, Switzerland, Jan 1

BROKER RATINGS SUMMARY: UBS And Credit Suisse Differ On Utility Stocks

GSK grabs Astra executive to replace exiting pharma head

LONDON, Jan 19 (Reuters) - GlaxoSmithKline said on Thursday that Abbas Hussain, its global head of pharmaceuticals, is leaving the company and will be replaced by Luke Miels from AstraZeneca. Hussain had been seen as a potential contender to take over from Chief Executive Andrew Witty, who

UPDATE 1-Drugmakers in Davos shift focus to chronic diseases of poor

(Adds Sanofi CEO comment on more ambitious programme from 2020) By Ben Hirschler DAVOS, Switzerland, Jan 18 (Reuters) - Two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said on Wednesday they would invest an initial $50 million over three yea

Drugmakers in Davos shift focus to chronic diseases of poor

By Ben Hirschler DAVOS, Switzerland, Jan 18 (Reuters) - Two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said on Wednesday they would invest $50 million over three years to fight cancer and other non-communicable diseases in poor countries. T

Sunday newspaper round-up: Hard Brexit, Putin, Hammond

(ShareCast News) - Theresa May will announce that Britain is seeking a clean and hard Brexit in a speech this week that will promise to create a "strong new partnership" with the European Union. The prime minister will finally lay her cards on the table, making clear that the UK is set to pull out o

UPDATE 2-BAT quits nicotine inhaler to focus on vaping

* BAT to transfer Voke rights back to Kind Consumer * Kind to search for new partners * BAT to concentrate efforts on vaping, tobacco-heating (Adds market data, background, byline) By Martinne Geller LONDON, Jan 5 (Reuters) - British American Tobacco (BAT) has quit plan

GSK launches big study to test new injection for HIV prevention

LONDON, Dec 20 (Reuters) - GlaxoSmithKline said on Tuesday its HIV unit ViiV Healthcare had started a large study to test an experimental long-acting injection for preventing the virus that causes AIDS. Reuters reported last month that the pre-exposure prophylaxis (PrEP) study with cabotegr

UPDATE 1-GSK's two-drug HIV therapy shines in two big studies

* GSK approach challenges Gilead's triple-drug strategy * Dolutegravir and rilpivirine work well in Phase III tests (Adds further reaction, more detail on competition) By Ben Hirschler LONDON, Dec 20 (Reuters) - GlaxoSmithKline's already fast-growing HIV drug business has rece

GSK's two-drug HIV therapy shines in two big studies

LONDON, Dec 20 (Reuters) - GlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to control the virus that causes AIDS. The approach is a departure from conventional tr

TOP NEWS: Glaxo's ViiV Gets Positive Results On Two-Drug HIV Treatment

GSK reports positive results from two-drug HIV regime study

(ShareCast News) - Pharmaceutical giant GlaxoSmithKline said it achieved positive results from a phase three HIV study, which assessed the efficiency of a two-drug regimen. ViiVHealthcare, which is majority owned by the company with stakes owned by Pfizer and Shionogi, said the first phase three stu

GSK boosts board-level science as new CEO prepares to take over

LONDON, Dec 19 (Reuters) - Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over. Incoming CEO Emma Walmsley, the first woman to lead a top global d